Clinical Trials Logo

Clinical Trial Summary

The SAVI Reflector is a nonradioactive infrared (IR)-activated electromagnetic wave device that can be implanted in the breast or lymph nodes under image-directed guidance, typically by mammography or sonography. Intraoperatively, the SCOUT hand-held device is then percutaneously applied to the breast or lymph node, creating an audible signal on the device console with a gradient which correlates to distance (in mm) from the target lesion and marker. The Savi Scout surgical guidance system was approved by the U.S. Food and Drug Administration in 2014. Furthermore, it was approved for long term use, with no restrictions on the length of time in 2017. The system consists of an implantable reflector with a 4-mm body size, preloaded in a 16-gauge deliverable needle, a hand-held probe and a console. The reflector consists of an IR light receptor, resistor switch and two antennae. This is placed into or near the target through a 16G needle under mammographic or sonographic guidance. The hand-held probe detects pulses of infrared (IR) light and radar wave signals, received by the console system, which then emits and receives signals back to the reflector to provide real time localization and target proximity information to the surgeon. The SCOUT console provides audible and visual feedback intraoperatively, the frequency of which increases as the handheld reader approaches the implanted reflector. After excision of the breast lesion, the handheld reader can be used to immediately confirm removal of the reflector, present in the lumpectomy specimen, and subsequent quiescence of radar signal in the breast.


Clinical Trial Description

Primary Endpoint: -To measure success of surgical retrieval of SAVI Scout placed at the time of initial, or mid-chemo, imaging studies. To demonstrate the successful excision of unifocal tumor tissue and/or tumor bed (after neoadjuvant chemotherapy). Other Endpoints: - Safety: Number of device-related adverse events. - Radiological Placement Radiologist-rated ease of placement using Likert scale - Accuracy of placement: - Accurate: Within the breast tumor - Marginal: Within the peritumoral tissue < or equal 5 mm - Inadequate: More than 5 mm - Unacceptable: Required additional localization device placement - Success rate of maintained position of SAVI Scout, measured on interval imaging: - Accurate: Within the breast tumor - Marginal: Within the peritumoral tissue < or equal 5 mm - Inadequate: More than 5 mm ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05118295
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Tanya Moseley, MD
Phone (713) 792-5755
Email [email protected]
Status Not yet recruiting
Phase Early Phase 1
Start date April 30, 2022
Completion date November 1, 2023

See also
  Status Clinical Trial Phase
Terminated NCT03520127 - A Registry Study Evaluating Outcomes in Breast Biopsy With the Intactâ„¢ Breast Lesion Excision System (BLES)
Active, not recruiting NCT03706534 - Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms N/A
Completed NCT00599105 - Angiogenesis in Early Breast Cancer for Prognosis Prediction N/A
Recruiting NCT01368939 - Investigation of High Resolution Nuclear Breast Imaging Camera (MBI) in Patients Administered Tc-99m Sestamibi (ROSE) N/A
Terminated NCT00934297 - Visualization Tool for Investigation of Breast Lesions N/A
Completed NCT03020888 - Magseed Magnetic Marker Localization N/A
Unknown status NCT00671385 - Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning N/A